Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corning Incorporated (GLW) vs Sana Biotechnology Inc (SANA) Price & Performance

Corning IncorporatedTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Corning Incorporated vs Sana Biotechnology Inc — how do they compare? Corning Incorporated trades at $158.23 (market cap $150.10B), while Sana Biotechnology Inc trades at $3.16 (market cap $987.94M). The key difference: Corning Incorporated is far larger — about 151.9× Sana Biotechnology Inc's market cap, and Corning Incorporated pays a 0.64% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

GLWSANA
Market Cap
$150.10B$987.94M
Sector
TechnologyHealth
52-Week High
$255.79$5.92
52-Week Low
$52.97$2.68
Enterprise Value
$158.27B$962.13M
Dividend Yield
0.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corning Incorporated

GLW is trading at $156.59, down 16.57% over 24 hours, reflecting a significant pullback from recent highs. The stock shows bearish technical signals but maintains strong fundamentals with revenue growth to $15.63 billion in 2025 and net income of $1.60 billion. Recent earnings beats and analyst optimism around AI-driven optical communication demand provide a positive backdrop despite near-term volatility.

The outlook for GLW is cautiously optimistic, with a consensus price target of $210.10 implying substantial upside. Key opportunities include partnerships with NVIDIA and Amazon in AI infrastructure, while risks involve high valuation multiples and sensitivity to tech sector sentiment. Long-term growth in 5G and automotive glass supports the investment case.

Sana Biotechnology Inc

Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.

The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Corning Incorporated

Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.

Read more on GLW

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA